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ABSTRACT
Among 200 isolates of Shigella from patients with
travellers’ diarrhoea, 12 isolates (four isolated in
1995–2000 and eight in 2001–2004) exhibited
quinolone resistance. Nine of these isolates orig-
inated from India. These resistant isolates had at
least one amino-acid substitution in GyrA. Quino-
lone resistance is increasing in Shigella spp.
causing travellers’ diarrhoea, and particularly
among isolates causing diarrhoea in travellers
returning from India.
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Diarrhoea is the most frequent pathology affect-
ing travellers to developing countries. Various
microorganisms have been identiﬁed as a cause of
travellers’ diarrhoea (TD), with Shigella spp. being
one of the groups detected most frequently [1].
Diarrhoea caused by Shigella spp. is characterised
by bloody stools containing mucus, with the
infecting organism usually having been acquired
by drinking contaminated water or eating un-
cooked food, although alternative transmission
mechanisms have also been described [2]. Shigella
spp. have been acquiring resistance progressively
to most commonly used antibiotics as a result of
the ability of these organisms to acquire resistance
genes located on mobile elements [3] and the
continuous selective pressure resulting from high
levels of antibiotic consumption [4]. Furthermore,
in some areas, the presence of poor quality
unlicensed antibacterial agents enhances the like-
lihood of development of resistance [5]. Quinol-
ones are no exception, with recent reports
showing increasing levels of resistance to these
agents, which have been considered to be the
treatment of choice for Shigella spp. during recent
years [6,7].
Antimicrobial resistance patterns differ accord-
ing to the geographical origin of strains [2]. Thus,
establishing the resistance proﬁle of microorgan-
isms causing TD in relation to their geographical
origin may allow the formulation of guidelines for
empirical treatment if necessary. The present
study therefore aimed to determine the levels of
resistance to quinolones in isolates of Shigella spp.
causing TD with various geographical origins,
and analysed target site mutations in the corre-
sponding genes.
The study included 200 isolates of Shigella spp.
(87 Shigella ﬂexneri, 106 Shigella sonnei, ﬁve Shigella
dysenteriae and two Shigella boydii); these isolates
were recovered from frozen stocks of 229 isolates
associated with TD between 1995 and 2004.
Identiﬁcation was performed by conventional
biochemical methods and serotyping [8]. Suscep-
tibility to nalidixic acid and ciproﬂoxacin was
determined by the agar dilution and disk-diffu-
sion methods in accordance with CLSI guidelines
[9]. Escherichia coli ATCC 25922, E. coli ATCC
35218 and Pseudomonas aeruginosa ATCC 27853
were used as quality control strains. When analy-
sing the variations in susceptibility levels, the
isolates were divided into two groups according
to the year of isolation: (i) 1995–2000; and (ii)
2001–2004. Mutations in the gyrA and parC genes
were detected by PCR as described previously
[10]. The Maentel Haenszel test was used to
establish statistical signiﬁcance.
Twelve (6%) of the 200 Shigella isolates showed
resistance or decreased susceptibility to nalidixic
acid; two of these 12 isolates were also fully-
resistant to ciproﬂoxacin (Fig. 1). All of these
isolates were from India or from Africa (Mali and
Equatorial Guinea). Of these, seven were identi-
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ﬁed as S. sonnei, four as S. ﬂexneri and one as
S. dysenteriae (Table 1, Fig. 1).
During the ﬁrst period, four (3.5%) of 90
isolates were resistant to quinolones, while eight
(9.3%) of 110 isolates were resistant during the
second period. Quinolone resistance among
S. sonnei isolates increased from 3.4% (two of 60
isolates) in the ﬁrst period to 10.9% (ﬁve of 46
isolates) in the second period; among the S. ﬂex-
neri isolates, resistance increased from 3.9% (two
of 51 isolates) in the ﬁrst period to 5.5% (two of 36
isolates) in the second period.
The single quinolone-resistant S. dysenteriae
isolate originated from the Indian subcontinent,
as did all the quinolone-resistant S. sonnei iso-
lates, while only one S. ﬂexneri isolate with
decreased susceptibility to quinolones had this
origin (Table 1). Among quinolone-resistant
S. sonnei isolates from India, a signiﬁcant in-
crease in resistance was observed, from 16.6%
(two of 12 isolates) in the ﬁrst period to 83.3%
(ﬁve of six isolates) in the second period
(p <0.03). When the isolates originating from
India were excluded, the overall level of nali-
dixic acid resistance was 1.7%, and no resistance
to ciproﬂoxacin was detected.
The quinolone resistance mechanism described
most frequently, both in Shigella spp. and in other
microorganisms, involves the presence of muta-
tions in the quinolone target site [4,11]. As
described previously for Enterobacteriaceae
[4,11], the present study revealed that nalidixic
acid resistance is related mainly to the presence of
a single amino-acid substitution at either posi-
tion 83 or position 87 of GyrA, while resistance to
ciproﬂoxacin is related to the presence of at least
one additional substitution in GyrA or ParC [4].
Other substitutions in GyrA or ParC, as well as in
GyrB or ParE, have been related less frequently to
the development of quinolone resistance [4].
These facts have been related to the proposed
mechanisms of interaction between quinolones
and their targets [12].
One S. ﬂexneri isolate without any mutations in
the quinolone target sites was detected, with
MICs of 0.06 mg ⁄L and 32 mg ⁄L for ciproﬂoxacin
and nalidixic acid, respectively. According to
disk-diffusion, this isolate had a consistent
NalICipS phenotype. These ﬁndings suggest the
presence of a different mechanism able to confer a
low level of nalidixic acid resistance. In-vitro
studies have demonstrated the presence of efﬂux
pumps in Shigella spp. that are able to confer
quinolone resistance in the absence of GyrA
Table 1. Geographical origin of Shi-
gella isolates resistant to quinolones
and their related molecular resis-
tance mechanism
Year Species Country
Nalidixic
acid MIC (mg ⁄L)
Ciproﬂoxacin
MIC (mg ⁄L) GyrA ParC
1998 Shigella sonnei India 64 0.06 Leu83 –
1998 Shigella ﬂexneri Mali 64 0.06 Leu83 –
1999 S. sonnei India 64 0.06 Tyr87 –
1999 S. ﬂexneri Mali 64 0.06 Leu83 –
2001 S. sonnei India 64 0.06 Tyr87 –
2002 S. sonnei India >128 8 Leu83, Asn87 Ile80
2003 S. ﬂexneri Equatorial Guinea 64 0.06 Tyr87 –
2003 S. sonnei India 64 0.06 Tyr87 –
2003 S. sonnei India 64 0.06 Tyr87 –
2004 S. ﬂexneri India 32 0.06 – –
2004 S. sonnei India >128 0.25 Leu83 –
2004 Shigella dysenteriae India >128 8 Leu83, Asn87 Ile80
Nal, nalidixic acid; Cip, ciproﬂoxacin.
(a) 
(b) 
Fig. 1. Distribution of (a) nalidixic acid MICs and (b)
ciproﬂoxacin MICs for Shigella ﬂexneri and Shigella sonnei
isolates.
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substitutions. A similar over-expressed efﬂux
pump might account for the NalICipS phenotype
in the above isolate.
Antibiotic consumption trends in a particular
region may inﬂuence the resistance proﬁles of
local bacteria. Quinolones have been used as the
drugs of choice for treating shigellosis in some
areas, including India [2,6]. The widespread use
of these agents might account for the high
percentage of quinolone-resistant isolates recov-
ered from the faeces of travellers to India. How-
ever, the low number of S. ﬂexneri isolates, and
the low levels of nalidixic acid resistance among
S. ﬂexneri isolates from travellers to India, as well
as the high prevalence of nalidixic acid-resistant
S. sonnei isolates originating from India, do not
agree with recent reports that have shown S. ﬂex-
neri to be the most prevalent Indian serotype, with
high levels of nalidixic acid and ciproﬂoxacin
resistance [6].
Although ﬂuoroquinolones remain active
against Shigella spp. causing TD, nalidixic acid
resistance is a well-established factor that pre-
dicts the development of ﬂuoroquinolone resis-
tance during therapy, as well as therapeutic
failure [13–15]. Thus, the present ﬁndings con-
traindicate the use of ﬂuoroquinolones as ﬁrst-
line treatment for cases of shigellosis imported
from India. Possible alternative treatments for
travel-associated shigellosis include ceftriaxone
or rifaximin [16,17].
In conclusion, this work revealed that quinol-
ones are not an appropriate treatment of choice
for Shigella spp. infections originating from
India, because of the high levels of nalidixic
acid resistance. Furthermore, in order to avoid
inadequate empirical antibiotic treatment, the
appearance of quinolone resistance in other
geographical areas should be monitored through
continuous surveillance. Alternative treatment
regimens are necessary to treat diarrhoea caused
by Shigella spp. in travellers returning from
India.
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